Affordable Access

What to add in with metformin in type 2 diabetes?

Authors
Publication Date
Disciplines
  • Biology
  • Medicine
  • Pharmacology

Abstract

This review considers the therapeutic choices currently faced by people with type 2 diabetes and those caring for them when glucose levels initially controlled with lifestyle management and metformin start to rise. While sulphonylureas are familiar agents and cheaper than other alternatives, they cause hypoglycaemia and modest weight gain, and robust outcome data are still lacking. Dipeptidyl peptidase 4 inhibitors ('gliptins') have an attractive pharmacological and adverse effect profile, but their effects on the cardiovascular system are also uncertain. Thiazolidinediones ('glitazones') are effective glucose-lowering agents, but cause weight gain and increase the risk of fracture, while the cardiovascular benefits hoped for in association with 'insulin-sensitization' have not been as expected. Glucagon-like peptide-1 agonists will not be acceptable as initial second-line agents for many people as they are injectable rather than oral. Well-powered 'head-to-head' clinical trials of adequate duration are therefore required to allow evidence-based decisions on second-line therapy

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

What to add in with metformin in type 2 diabetes?

on QJM : monthly journal of the A... March 2011

[Metformin in type 2 diabetes: what if we get it w...

on La Presse Médicale February 2013

What comes after metformin for type 2 diabetes.

on The Medical letter on drugs an... Jul 23, 2012
More articles like this..